Aptus Pharma — 360° view

Aptus Pharma, a company in the Pharmaceuticals industry, reported revenue of ₹49 crore and net profit of ₹5.08 crore for the September 2026 quarter.

Aptus Pharma (BSE: APPL) closed at ₹487.45 on 20 Nov 2026, up 692.6% over the past year. Its market capitalisation is ₹836 crore and it trades at 105.2 times earnings.

Share price
₹487.45 (20 Nov 2026)
Market cap
₹836 Cr (20 Nov 2026)
P/E
105.16 (20 Nov 2026)
Revenue
₹49 Cr (September 2026 quarter)
Net profit
₹5 Cr (September 2026 quarter)
ROCE
30.0% (FY26)
ROE
30.5% (FY26)
Book value
₹16.6 (FY26)
Dividend yield
0.00% (FY26)
52-week high / low
₹510.90 / ₹60.00 (20 Nov 2026)
1-year return
692.6% (to 20 Nov 2026)
Sector
Healthcare
Industry
Pharmaceuticals
Symbol
BSE: APPL

Incorporated in 2010, Aptus Pharma Ltd is engaged in the business of marketing and distribution of finished pharmaceutical formulations.

Descriptive research only, not investment advice. Evenstocks is not a SEBI-registered investment adviser.